Latest Regulatory News

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

AEMO forecasts a severe domestic gas shortage in Western Australia from 2028, spotlighting H3 Energy’s Warro gas field as a critical potential solution amid rising prices and technical hurdles.

360 Capital Group (ASX, TGP) has received an unconditional on-market takeover bid from TT Investments at $0.31 per stapled security. The Independent Board Committee unanimously recommends acceptance, supported by an Independent Expert's fair and reasonable opinion.

European Metals Holdings has released a Definitive Feasibility Study confirming the Cinovec Lithium Project as a long-life, battery-grade lithium carbonate producer strategically positioned to supply Europe's electric vehicle and energy storage sectors.

Caravel Minerals reports substantial progress on its Definitive Feasibility Study for the Caravel Copper Project, advancing engineering, environmental approvals, and strategic partnerships toward development.

The Supreme Court of New South Wales has approved Southern Cross Media's acquisition of Seven West Media, setting the stage for a significant media industry consolidation early next year.

Janus Henderson Investors has announced the distribution timetable for its Global Sustainable Equity Active ETF for the period ending December 2025, outlining key dates and reinvestment options for investors.

Scorpion Minerals has executed a binding option agreement to acquire the Old Prospect tenements within its Pharos Gold Project, adding a JORC-compliant resource of over 21,600 ounces of gold. The acquisition consolidates tenure along a highly prospective 5km structural corridor in Western Australia’s Murchison region.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.